Current partner codePEPTIDESDE
NCT06108362·Phase 4·INTERVENTIONAL

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

Status

Unknown

Phase

Phase 4

Enrollment

104

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

Full detailed description

acute kidney injury is a relatively common complication in patients with liver transplantation. Most centers have established prediction models for acute kidney injury after liver transplantation, but the incidence cannot be reduced through perioperative anesthesia management. As an vasopressin receptor agonist, terlipressin can increase blood pressure and improve kidney perfusion at the same time, and perioperative application may reduce the incidence of postoperative acute kidney injury

Interventions

Treatment arms and agents.

DRUG

Terlipressin

The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins

DRUG

normal saline

The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins

Timeline

From registration to results.

  1. First posted

    Oct 31, 2023

  2. Study start

    Aug 18, 2023

  3. Primary completion

    Jun 30, 2024

  4. Study completion

    Jun 30, 2024

  5. Results posted

    Not reported

  6. Registry updated

    Oct 31, 2023

Outcomes

What the study measures.

Primary outcomes

Incidence of acute kidney injury after liver transplantation

Time frame · in 7 days

acute kidney injury diagnostic criteria (2012 edition)

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
70 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * 1\) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent Exclusion Criteria: * Patients \<18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Beijing Tsinghua Chang Gung Hospital

Beijing, Beijing Municipality, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Terlipressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.